Veru (NASDAQ:VERU) Upgraded at Wall Street Zen

Veru (NASDAQ:VERU – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Monday, Wall Street Zen reports.

Several other research analysts have also recently issued reports on the company. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 10th. Westpark Capital began coverage on Veru in a report on Tuesday, October 6th. They set a “buy” rating on the stock. Finally, Oppenheimer restated an “outperform” rating on shares of Veru in a research note on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.50.

Read Our Latest Stock Report on VERU

Veru Price Performance

VERU opened at $2.09 on Monday. The stock’s 50 day moving average price is $2.35 and its 200 day moving average price is $2.47. The stock has a market cap of $35.63 million, a P/E ratio of -3.03 and a beta of -1.20. Veru has a 12 month low of $2.04 and a 12 month high of $7.33.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares during the period. Renaissance Technologies LLC bought a new stake in Veru in the first quarter worth about $153,000. Finally, FNY Investment Advisers LLC bought a new stake in Veru in the second quarter worth about $328,000. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

(Get Free Report)

Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.

Read More

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.